Rafael (NYSE:RFL) versus Traws Pharma (NASDAQ:TRAW) Head to Head Analysis

Traws Pharma (NASDAQ:TRAW) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Traws Pharma and Rafael, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1	4	0	0	1.80
Rafael	1	0	0	0	1.00

Traws Pharma presently has a consensus price target of $1.00, indicating a potential upside of 172.85%. Given Traws Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Traws Pharma is more favorable than Rafael.

Volatility & Risk

Traws Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Rafael has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

Valuation and Earnings

This table compares Traws Pharma and Rafael”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79 million	2.02	$9.17 million	($1.74)	-0.21
Rafael	$920,000.00	73.20	-$30.52 million	($0.68)	-1.90

Traws Pharma has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Traws Pharma and Rafael’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-23,868.92%	-165.52%
Rafael	-3,321.74%	-41.27%	-35.32%

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.